Copyright
©The Author(s) 2024.
World J Hepatol. Aug 27, 2024; 16(8): 1131-1144
Published online Aug 27, 2024. doi: 10.4254/wjh.v16.i8.1131
Published online Aug 27, 2024. doi: 10.4254/wjh.v16.i8.1131
Table 4 Univariable Kaplan-Meier survival analysis
OS | RFS | |||||
De, n (%) | MST (95%CI) | P value | Re, n (%) | MRT (95%CI) | P value | |
Age (years) | 0.71 | 0.97 | ||||
< 49 | 79 (80.6) | 27.00 (22.12-31.88) | 68 (69.4) | 27.00 (20.88-33.12) | ||
≥ 49 | 71 (84.5) | 23.00 (19.04-26.96) | 56 (66.7) | 24.00 (18.84-29.16) | ||
Gender | 0.68 | 0.55 | ||||
Male | 113 (83.7) | 26.00 (2299-29.01) | 91 (67.4) | 24.00 (17.96-30.05) | ||
Female | 37 (78.7) | 26.00 (21.71-30.29) | 33 (70.2) | 25.00 (17.96-30.04) | ||
Race | 0.76 | 0.26 | ||||
Han | 74 (83.1) | 27.00 (22.55-31.76) | 65 (73.0) | 25.00 (19.01-30.99) | ||
Others | 76 (81.7) | 26.00 (21.88-30.81) | 59 (63.4) | 25.00 (15.63-34.37) | ||
Smoking | 0.06 | 0.01 | ||||
No | 114 (82.6) | 24.00 (20.33-27.67) | 101 (73.2) | 24.00 (18.62-29.38) | ||
Yes | 36 (81.8) | 27.00 (19.67-34.43) | 23 (52.3) | 33.00 (15.27-50.74) | ||
Drinking | 0.10 | 0.03 | ||||
No | 110 (81.5) | 24.00 (20.17-27.83) | 97 (71.9) | 24.00 (18.44-29.56) | ||
Yes | 40 (85.1) | 27.00 (22.53-31.47) | 27 (57.4) | 30.00 (15.73-44.27) | ||
HBsAg | 0.26 | 0.05 | ||||
Negative | 44 (69.8) | 28.00 (24.38-31.62) | 34 (54.0) | 29.00 (18.01-40.00) | ||
Positive | 106 (89.1) | 24.00 (19.47-28.53) | 90 (75.6) | 22.00 (16.52-27.48) | ||
Anti-HCV | 0.45 | 0.88 | ||||
Negative | 123 (82.6) | 24.00 (19.69-28.31) | 99 (66.4) | 24.00 (17.81-30.19) | ||
Positive | 27 (81.8) | 28.00 (23.80-32.20) | 25 (75.8) | 28.00 (20.61-35.39) | ||
AFP | 1.85 × 10-9 | 1.03 × 10-6 | ||||
Negative | 44 (68.7) | 41.00 (29.46-52.54) | 35 (54.7) | 40.00 (30.18-49.82) | ||
Positive | 106 (89.8) | 20.00 (17.24-22.77) | 89 (75.4) | 17.00 (13.10-20.90) | ||
AFB1 exposure | 1.31 × 10-9 | 9.39 × 10-10 | ||||
Low | 58 (77.3) | 36.00 (26.75-45.25) | 38 (50.7) | 43.00 (33.01-52.99) | ||
High | 92 (86.0) | 20.00 (17.22-22.78) | 86 (80.4) | 18.00 (14.25-21.75) | ||
Tumor size | 5.52 × 10-8 | 5.3 × 10-6 | ||||
≤ 5 cm | 37 (66.1) | 39.00 (27.27-50.73) | 31 (55.4) | 40.00 (31.01-48.99) | ||
> 5 cm | 113 (89.7) | 19.00 (15.84-22.16) | 93 (73.8) | 16.00 (12.48-19.52) | ||
ES grade | 3.82 × 10-4 | 9.07 × 10-3 | ||||
Low | 75 (79.8) | 33.00 (28.08-37.92) | 61 (64.9) | 30.00 (25.23-34.77) | ||
High | 75 (85.2) | 20.00 (17.07-22.93) | 63 (71.6) | 19.00 (13.83-24.17) | ||
TNM stage | 7.40 × 10-17 | 4.47 × 10-11 | ||||
I | 24 (80.0) | 45.00 (35.63-54.37) | 19 (63.3) | 37.00 (28.77-45.23) | ||
II | 59 (75.6) | 27.00 (23.79-30.21) | 47 (60.3) | 29.00 (21.89-36.11) | ||
III | 67 (90.5) | 12.00 (8.63-15.37) | 58 (78.4) | 10.00 (6.26-13.75) | ||
Liver cirrhosis | 0.93 | 0.43 | ||||
No | 45 (80.4) | 27.00 (21.49-32.52) | 34 (60.7) | 27.00 (21.56-32.44) | ||
Yes | 105 (83.3) | 25.00 (21.51-28.49) | 90 (71.4) | 24.00 (19.69-28.31) | ||
MVD | 7.60 × 10-11 | 1.07 × 10-11 | ||||
Low | 68 (75.6) | 34.00 (31.65-36.35) | 49 (54.4) | 36.00 (27.49-44.51) | ||
High | 82 (89.1) | 15.00 (11.87-18.13) | 75 (81.5) | 13.00 (9.00-16.01) | ||
PVTT | 1.50 × 10-6 | 9.99 × 10-7 | ||||
Negative | 103 (81.1) | 29.00 (24.61-33.39) | 80 (63.0) | 30.00 (25.71-34.29) | ||
Positive | 47 (85.5) | 12.00 (7.96-16.04) | 44 (80.0) | 8.00 (5.09-10.91) | ||
MVI | 6.65 × 10-8 | 1.55 × 10-7 | ||||
Negative | 95 (81.9) | 29.00 (24.69-33.31) | 73 (62.9) | 30.00 (25.90-34.10) | ||
Positive | 55 (83.3) | 11.00 (6.66-15.34) | 51 (77.3) | 8.00 (4.38-11.62) | ||
TIMP3 | 3.91 × 10-11 | 1.89 × 10-6 | ||||
LTE | 86 (96.6) | 18.00 (16.64-21.36) | 70 (78.7) | 16.00 (12.31-19.69) | ||
HTE | 64 (68.8) | 36.00 (28.20-43.81) | 54 (58.1) | 32.00 (22.79-41.21) |
-
Citation: Liang QJ, Long QQ, Tian FQ, Su QY, Zhu XY, Long XD. Tissue inhibitor of metalloproteinase-3 expression affects clini
copathological features and prognosis of aflatoxin B1-related hepatocellular carcinoma. World J Hepatol 2024; 16(8): 1131-1144 - URL: https://www.wjgnet.com/1948-5182/full/v16/i8/1131.htm
- DOI: https://dx.doi.org/10.4254/wjh.v16.i8.1131